N,N-Diallyltryptamine (DALT) is a tryptamine derivative which has been identified as a new psychoactive substance.[2][3] It has been used as an intermediate in the preparation of radiolabeled diethyltryptamine.[4]

Dosage and effects

According to Alexander Shulgin in TiHKAL, the dosage of DALT is >40 mg orally and its duration is unknown.[1] Its effects have not been described.[1]

Pharmacology

DALT activities
Target Affinity (Ki, nM)
5-HT1A 100
5-HT1B >10,000
5-HT1D 689
5-HT1E 378
5-HT1F ND
5-HT2A 701
5-HT2B 61
5-HT2C 385
5-HT3 >10,000
5-HT4 ND
5-HT5A >10,000
5-HT6 1,718
5-HT7 >10,000
α1A 1,663
α1B 1,369
α1D >10,000
α2A 124
α2B 305
α2C 901
β1–β3 >10,000
D1, D2 >10,000
D3 672
D4, D5 >10,000
H1 127
H2–H4 >10,000
M1–M5 >10,000
I1 ND
σ1 101 (rat)
σ2 356 (rat)
TAAR1Tooltip Trace amine-associated receptor 1 ND
MORTooltip μ-Opioid receptor, DORTooltip δ-Opioid receptor >10,000
KORTooltip κ-Opioid receptor 2,477
SERTTooltip Serotonin transporter 150 (Ki)
NETTooltip Norepinephrine transporter 1,121 (Ki)
DATTooltip Dopamine transporter 1,406 (Ki)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [5][6][7][8]

The receptor interactions of DALT have been studied.[5][6][7][8] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[9]

See also

References

  1. ^ a b c Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  2. ^ Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH (October 2015). "Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS" (PDF). Analytical and Bioanalytical Chemistry. 407 (25): 7831–42. doi:10.1007/s00216-015-8955-0. PMID 26297461. S2CID 26086597.
  3. ^ Michely JA, Brandt SD, Meyer MR, Maurer HH (February 2017). "n, and LC-HR-MS/MS" (PDF). Analytical and Bioanalytical Chemistry. 409 (6): 1681–1695. doi:10.1007/s00216-016-0117-5. PMID 27933361. S2CID 206920201.
  4. ^ Brandt SD, Tirunarayanapuram SS, Freeman S, Dempster N, Barker SA, Daley PF, et al. (2008). "Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (14): 423–429. doi:10.1002/jlcr.1557.
  5. ^ a b "Kᵢ Database". PDSP. 28 March 2025. Retrieved 28 March 2025.
  6. ^ a b Liu, Tiqing. "BindingDB BDBM50140058 CHEMBL3752576". BindingDB. Retrieved 28 March 2025.
  7. ^ a b Cozzi NV, Daley PF (February 2016). "Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines" (PDF). Bioorganic & Medicinal Chemistry Letters. 26 (3): 959–964. doi:10.1016/j.bmcl.2015.12.053. PMID 26739781.
  8. ^ a b Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (November 2018). "Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs" (PDF). Neuropharmacology. 142: 231–239. doi:10.1016/j.neuropharm.2018.02.028. PMC 6230509. PMID 29499272.
  9. ^ Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Curr Top Behav Neurosci. 36: 159–199. doi:10.1007/7854_2016_466. PMC 5787039. PMID 28224459. The HTR has also been observed in rodents treated with N-methyl-N-ethyltryptamine (MET), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-diisopropyltryptamine (DIPT), and N,N-diallyltryptamine (DALT) (Fantegrossi et al. 2008; Smith et al. 2014; Carbonaro et al. 2015; Halberstadt and Klein, unpublished observations).
Allikas: https://en.wikipedia.org/wiki/DALT
No tags for this post.